ClinicalTrials.gg
CompletedNCT07268430Updated Dec 5, 2025

Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia

An interventional study of Paliperidone Palmitate Injection(PP1M) and Paliperidone Palmitate Injection(PP1M)(Reference Group) in Schizophrenia, sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Dec 2023, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
43rd of 115
256 · median 178
Started
2023
with 1 other
No phase
4 of 115
1 open now
Registered
113th of 115
by date
Lead sponsor
2 of 115
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 43rd largest by enrollment, is one of 2 that started in 2023, is one of 4 with no phase, and was the 113th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

This multicenter, randomized, open-label, parallel-group, multiple-dose study is designed to evaluate the bioequivalence, at pharmacokinetic steady state, of a paliperidone palmitate injection manufactured by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (Test Group) and a paliperidone palmitate injection manufactured by Janssen Pharmaceutica N.V. (Reference Group) in patients with schizophrenia in China. Bioequivalence will be assessed based on steady-state pharmacokinetic parameters after repeated intramuscular administration (e.g., Cmax,ss and AUCτ). The safety and tolerability of the test and reference products will also be evaluated.

Read the detailed description

Purpose: This trial was conducted to evaluate the bioequivalence of a test (T) and a reference (R) formulation of once-monthly paliperidone palmitate (PP1M) in patients with schizophrenia.

Patients and methods: In this randomized, open-label, parallel-group, steady-state bioequivalence study, patients with stabilized schizophrenia were randomized 1:1 to receive T or R formulation. The regimen was 150 mg deltoid on Day 1, then 100 mg deltoid on Day 8, followed by five subsequent 100 mg gluteal injections every 28 days. The primary objective was to demonstrate steady-state bioequivalence. The primary endpoints were key pharmacokinetic parameters of paliperidone, including steady-state maximum concentration (Cmax,ss) and the area under the concentration-time curve over a dosing interval at steady state (AUCτ,ss). Bioequivalence was shown if the 90% confidence interval (CI) for the ratio of the geometric least squares means of the pharmacokinetic parameters (AUCτ,ss and Cmax,ss) fell within 80%-125%.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 65 years inclusive at the time of consent.
  2. Diagnosis of schizophrenia (ICD-10 criteria) prior to screening.
  3. PANSS total score ≤70 at screening and at baseline.
  4. CGI-S score ≤4 at screening and at baseline.
  5. Body weight at screening: ≥50.0 kg (male) or ≥45.0 kg (female); (BMI) 19.0 to 35.0 kg/m2 (inclusive).
  6. The participant and/or partner have no plans for pregnancy during the study and for 6 months after the last dose, and agree to use effective (oral contraceptives are not allowed).
  7. Signed and willingness and ability to comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected to the study drug (paliperidone palmitate) or any of its components.
  2. Diagnosis per ICD-10 or of any psychiatric disorder other than schizophrenia.
  3. diseases or abnormalities, as judged by the investigator, in the respiratory, cardiovascular, gastrointestinal, genitourinary, reproductive, nervous, endocrine, or immune systems that may affect participant safety or interfere with study participation.
  4. Laboratory abnormalities at screening or baseline meeting any of the following: (1) total >1.5 × , or or ALT >2 × ULN; (2) (CLcr) \<90 mL/min; (3) white blood cell count \<3 × 10\^9/L, or \<1.5 × 10\^9/L, or \<80 × 10\^9/L.
  5. History of orthostatic hypotension or syncope due to orthostatic hypotension (except if stable for >6 months); or at screening/baseline, a decrease in systolic blood pressure ≥20 mmHg or diastolic blood pressure ≥10 mmHg within 3 minutes after changing from supine to standing.
  6. Congenital long syndrome; uncontrolled or significant cardiovascular disease, including congestive heart failure of class II or higher, unstable angina, or myocardial infarction within 6 months prior to first study dose; significant arrhythmias (including frequent premature ventricular contractions), or clinically significant arrhythmias requiring treatment at screening; QTc >450 ms (male) or >460 ms (female) at screening or baseline; risk factors for torsades de pointes or sudden death (e.g., bradycardia, clinically significant hypokalemia or hypomagnesemia, current use of medications that prolong QTc); or other clinically significant abnormalities as judged by the investigator.
  7. Past or current neuroleptic malignant syndrome.
  8. Parkinson's disease, Lewy body dementia, or dementia-related psychosis.
  9. Past or current seizure or convulsive disorders (except childhood febrile seizures), or stroke or within 1 year prior to consent.
  10. History of tardive dyskinesia induced by risperidone, paliperidone, or other antipsychotics.
  11. Uncontrolled diabetes mellitus, or ≥7% at screening or baseline.
  12. Electroconvulsive therapy within 28 days prior to consent.
  13. Blood loss ≥400 mL within 3 months prior to consent, or ≥200 mL within 1 month prior to consent due to donation, surgery, or other causes.
  14. Esophageal motility disorders, dysphagia, or other conditions that confer risk of aspiration pneumonia.
  15. Positive tests for surface antigen, antibody, antibody, or treponemal (syphilis) antibody.
  16. Harmful alcohol use: >14 units per week (1 unit = 360 mL beer, or 150 mL wine, or 45 mL spirits).
  17. Use of any drug within 1 month prior to first study dose (excluding paliperidone palmitate or placebo), or prior participation in a gene therapy or cell therapy clinical trial such that, in the investigator's judgment, the participant is not suitable for this study.
  18. Major surgery within 3 months prior to consent, or planned surgery within 1 month after study completion.
  19. High suicide risk: C-SSRS suicidal ideation items 4 or 5 answered "Yes" within the past 6 months at screening/baseline; or suicidal behavior within the past 6 months; or, in the investigator's judgment, a serious risk of suicide.
  20. Prohibited medications/treatments: (1) ziprasidone or thioridazine within 4 weeks prior to consent; (2) any other long-acting injectable antipsychotic received within one labeled dosing interval prior to consent (except risperidone microspheres), or receipt of risperidone microspheres (e.g., Hengde®) within 6 weeks prior to consent; (3) non-selective or irreversible monoamine oxidase inhibitors within 1 month prior to first dose; (4) strong or moderate inhibitors or inducers of , CYP2D6, or P-gp within 2 weeks prior to consent.
  21. Pregnant, breastfeeding, or planning pregnancy; except for women who are for ≥1 year or surgically sterile (e.g., bilateral tubal ligation with non-recanalized tubes, bilateral oophorectomy, or hysterectomy).
  22. Drug abuse history, illicit drug use, or positive drug abuse screening within 1 year prior to consent.
  23. Clinically significant history of syncope related to needles or blood draws. Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    Paliperidone Palmitate 1-Month Formulation (PP1M) (Test Group)

    Participants will receive paliperidone palmitate injection manufactured by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., administered intramuscularly. Dosing regimen: 150 mg on Day 1 and 100 mg on Day 8, followed by 100 mg every 28 days (starting Day 1 regimen); or 100 mg every 28 days (starting Day 36 regimen).

    Drug: Paliperidone Palmitate Injection(PP1M) · Drug: Paliperidone Palmitate Injection(PP1M)(Reference Group)

  • Active comparator
    Paliperidone Palmitate 1-Month Formulation (PP1M) (Reference Group)

    Participants will receive paliperidone palmitate injection (Invega Sustenna®) manufactured by Janssen Pharmaceutica N.V., administered intramuscularly. Dosing regimen: 150 mg on Day 1 and 100 mg on Day 8, followed by 100 mg every 28 days (starting Day 1 regimen); or 100 mg every 28 days (starting Day 36 regimen).

    Drug: Paliperidone Palmitate Injection(PP1M) · Drug: Paliperidone Palmitate Injection(PP1M)(Reference Group)

Interventions

  • Paliperidone palmitate injection will be administered intramuscularly according to two dosing regimens based on participants' prior exposure to paliperidone palmitate: 1. Participants with no prior use of paliperidone palmitate injection, or whose last dose was administered more than 6 months ago (for the once-monthly formulation), or more than 5 half-lives ago (for the once-every-3-months formulation): Day 1: 150 mg, deltoid muscle Day 8: 100 mg, deltoid muscle Followed by 100 mg every 28 days thereafter Approximate treatment duration: 148 days 2. Participants who have previously received at least 3 injections (including 150 mg Day 1 loading dose and 100 mg Day 8 loading dose, deltoid muscle) of the once-monthly formulation (100 mg) of paliperidone palmitate and whose last dose was given within 4 to 6 weeks prior to enrollment: Continue with 100 mg every 28 days Approximate treatment duration: 113 days

    Also known as: SYHF2036

  • Paliperidone palmitate injection will be administered intramuscularly according to two dosing regimens based on participants' prior exposure to paliperidone palmitate: 1. Participants with no prior use of paliperidone palmitate injection, or whose last dose was administered more than 6 months ago (for the once-monthly formulation), or more than 5 half-lives ago (for the once-every-3-months formulation): Day 1: 150 mg, deltoid muscle Day 8: 100 mg, deltoid muscle Followed by 100 mg every 28 days thereafter Approximate treatment duration: 148 days 2. Participants who have previously received at least 3 injections (including 150 mg Day 1 loading dose and 100 mg Day 8 loading dose, deltoid muscle) of the once-monthly formulation (100 mg) of paliperidone palmitate and whose last dose was given within 4 to 6 weeks prior to enrollment: Continue with 100 mg every 28 days Approximate treatment duration: 113 days

    Also known as: Invega Sustenna

06

What researchers measure

Primary outcomes

  1. Title:Steady-State Peak Concentration (Cmax,ss) of Paliperidone After Intramuscular Administration.

    Steady-state maximum plasma concentration (Cmax,ss) will be determined to assess bioequivalence between the test and reference formulations of paliperidone palmitate injection after multiple intramuscular doses in patients with schizophrenia.

    Time frame: Day148~Day176

  2. Area Under the Concentration-Time Curve over Dosing Interval (AUCτ,ss) of Paliperidone After Intramuscular Administration.

    Area under the plasma concentration-time curve during the dosing interval (AUCτ,ss) will be determined to assess bioequivalence between the test and reference formulations of paliperidone palmitate injection after multiple intramuscular doses in patients with schizophrenia.

    Time frame: Day148~Day176

Secondary outcomes

  1. Steady-State Trough Concentration (Ctau,ss)

    Steady-state plasma trough concentration (Ctau,ss) of paliperidone will be measured to further characterize pharmacokinetics and assess bioequivalence between test and reference group.

    Time frame: Day1~Day176

  2. Steady-State Average Concentration (Cav,ss)

    Average plasma concentration during the dosing interval (Cav,ss) will be evaluated at steady state.

    Time frame: Day1~Day176

  3. Steady-State Minimum Concentration (Cmin,ss)

    Minimum plasma concentration during the dosing interval (Cmin,ss) at steady state will be determined.

    Time frame: Day1~Day176

  4. Time to Maximum Concentration at Steady State (Tmax,ss)

    The time to reach maximum plasma concentration (Tmax,ss) will be assessed at steady state.

    Time frame: Day1~Day176

  5. Degree of Fluctuation (DF) and Swing at Steady State

    The degree of fluctuation (DF) and swing of paliperidone plasma concentrations will be calculated at steady state.

    Time frame: Day1~Day176

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Number and percentage of participants experiencing ≥1 treatment-emergent adverse event (TEAE) after first dose; events coded by MedDRA (System Organ Class and Preferred Term); severity (mild/moderate/severe) and relationship to study drug assessed by investigator.

    Time frame: Day1~Day176

  7. Number of Participants With Serious Adverse Events (SAEs)

    Number and percentage of participants experiencing ≥1 SAE, defined per ICH-GCP criteria; events coded by MedDRA (SOC/PT).

    Time frame: Day1~Day176

  8. Clinical Global Impression-Severity (CGI-S)

    Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score Mean (SD) change in CGI-S score from baseline to end of treatment. Clinical Global Impression - Severity (CGI-S): The Clinical Global Impression - Severity Scale ranges from 1 to 7 (1 = normal, not at all ill; 7 = among the most extremely ill), and higher scores indicate worse clinical severity (worse outcome).

    Time frame: Day1~Day176

  9. Proportion of Participants With Suicidal Ideation or Behavior (C-SSRS)

    Number and percentage of participants with suicidal ideation (items 4 or 5) and/or any suicidal behavior on the Columbia-Suicide Severity Rating Scale (C-SSRS). Columbia-Suicide Severity Rating Scale (C-SSRS): The Columbia-Suicide Severity Rating Scale rates suicidal ideation severity from 1 to 5 (0 = no suicidal ideation; 5 = most severe ideation), while suicidal behavior is recorded as present/absent; higher ideation category indicates a worse outcome (greater suicide risk).

    Time frame: Day1~Day176

  10. Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Score

    Mean (SD) change in BARS global score from baseline to end of treatment. Barnes Akathisia Rating Scale (BARS): The Barnes Akathisia Rating Scale global score ranges from 0 to 5 (0 = no akathisia; 5 = severe akathisia), and higher scores indicate more severe akathisia (worse outcome).

    Time frame: Day1~Day176

  11. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score

    Mean (SD) change in AIMS total score from baseline to end of treatment. Abnormal Involuntary Movement Scale (AIMS): The Abnormal Involuntary Movement Scale total score commonly uses the sum of items 1-7 and ranges from 0 to 28 (0 = no abnormal movements; 28 = maximum severity on rated items); higher scores indicate more severe abnormal involuntary movements (worse outcome).

    Time frame: Day1~Day176

  12. Change From Baseline in Simpson-Angus Scale (SAS) Total Score

    Mean (SD) change in SAS total score from baseline to end of treatment. Simpson-Angus Scale (SAS): The Simpson-Angus Scale total score ranges from 0 to 40 (10 items each scored 0-4), and higher scores indicate more severe drug-induced parkinsonism (worse outcome).

    Time frame: Day1~Day176

07

Study locations

1 site
  • Beijing Anding Hospital Capital Medical University
    Beijing, Beijing Municipality, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Dec 2024, 12 months.

Of 773 interventional studies with no phase under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Dec 5, 2025
StartActual
Dec 18, 2023
Primary completionActual
Dec 25, 2024
CompletionActual
Dec 25, 2024
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07268430
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Dec 18, 2023
Primary completion
Dec 25, 2024
Completion
Dec 25, 2024
Last update
Dec 5, 2025

Study contacts

Gang Wang, M.D.
study chair · Beijing Anding Hospital Capital Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion